Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients
Purpose Tacrolimus is a novel effective immunosuppressant for myasthenia gravis (MG) patients. However, the narrow therapeutic window, and high inter- and intrapatient variation in bioavailability largely limited its clinical application. This article intended to find the SNPs influencing clinical outcome and discover the possible mechanisms. Methods Based on the tagSNPs genotyped by Improved Multiple Ligase Detection Reaction, Plink 1.07 was used to find the SNPs having close interaction to tacrolimus serum concentration, QMG score changes or even reasonable drug dose. Then we searched several databases to predict the possible miRNA binding rs15524 sequence. Based on the prediction, dual-luciferase reporter assay and miRNA transfection were used to discover the mechanism of how SNP rs15524 controls tacrolimus serum concentration through influencing CYP3A5 expression. Results In this article, we found multiple SNPs on CYP3A4, CYP3A5, FKBP1A, NFATC2 genes were predicted closely related to tacrolimus serum concentration, therapeutic effect which reflected by QMG score changes or even reasonable drug dose. After in silico miRNA selection, possible relationship between hsa-miR-500a and rs15524 was found. With the help of dual-luciferase reporter assay, wild-type rs15524 (T allele) was found having a stronger binding affinity for hsa-miR-500a. Higher expression of CYP3A5 may also led by lower hsa-miR-500a level. Conclusions SNP rs15524 may control CYP3A5 expression by affecting the binding affinity between CYP3A5 3’UTR and hsa-miR-500a. Wild type (T allele) 3’UTR of CYP3A5 has stronger binding affinity to hsa-miR-500a and cause lower CYP3A5 expression and higher tacrolimus serum concentration..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
European journal of clinical pharmacology - 76(2020), 5 vom: 18. Jan., Seite 659-671 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meng, Huan-Yu [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| doi: |
10.1007/s00228-019-02803-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR039420485 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR039420485 | ||
| 003 | DE-627 | ||
| 005 | 20230519091053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00228-019-02803-0 |2 doi | |
| 035 | |a (DE-627)SPR039420485 | ||
| 035 | |a (SPR)s00228-019-02803-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Meng, Huan-Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose Tacrolimus is a novel effective immunosuppressant for myasthenia gravis (MG) patients. However, the narrow therapeutic window, and high inter- and intrapatient variation in bioavailability largely limited its clinical application. This article intended to find the SNPs influencing clinical outcome and discover the possible mechanisms. Methods Based on the tagSNPs genotyped by Improved Multiple Ligase Detection Reaction, Plink 1.07 was used to find the SNPs having close interaction to tacrolimus serum concentration, QMG score changes or even reasonable drug dose. Then we searched several databases to predict the possible miRNA binding rs15524 sequence. Based on the prediction, dual-luciferase reporter assay and miRNA transfection were used to discover the mechanism of how SNP rs15524 controls tacrolimus serum concentration through influencing CYP3A5 expression. Results In this article, we found multiple SNPs on CYP3A4, CYP3A5, FKBP1A, NFATC2 genes were predicted closely related to tacrolimus serum concentration, therapeutic effect which reflected by QMG score changes or even reasonable drug dose. After in silico miRNA selection, possible relationship between hsa-miR-500a and rs15524 was found. With the help of dual-luciferase reporter assay, wild-type rs15524 (T allele) was found having a stronger binding affinity for hsa-miR-500a. Higher expression of CYP3A5 may also led by lower hsa-miR-500a level. Conclusions SNP rs15524 may control CYP3A5 expression by affecting the binding affinity between CYP3A5 3’UTR and hsa-miR-500a. Wild type (T allele) 3’UTR of CYP3A5 has stronger binding affinity to hsa-miR-500a and cause lower CYP3A5 expression and higher tacrolimus serum concentration. | ||
| 650 | 4 | |a Myasthenia gravis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SNP |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tacrolimus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a MiRNA |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Li, Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Wan-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Cheng-Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Xiao-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Qiu |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Yu-Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhi-Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Zhao-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Li-Qun |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Huan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical pharmacology |d Berlin : Springer, 1968 |g 76(2020), 5 vom: 18. Jan., Seite 659-671 |w (DE-627)SPR002560860 |w (DE-600)1459058-X |x 1432-1041 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2020 |g number:5 |g day:18 |g month:01 |g pages:659-671 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00228-019-02803-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.40 |q ASE |
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 76 |j 2020 |e 5 |b 18 |c 01 |h 659-671 | ||